University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB, UK.
Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, ST4 7QB, UK.
BMC Med Res Methodol. 2019 Jul 31;19(1):166. doi: 10.1186/s12874-019-0808-7.
Analysis of competing risks is commonly achieved through a cause specific or a subdistribution framework using Cox or Fine & Gray models, respectively. The estimation of treatment effects in observational data is prone to unmeasured confounding which causes bias. There has been limited research into such biases in a competing risks framework.
We designed simulations to examine bias in the estimated treatment effect under Cox and Fine & Gray models with unmeasured confounding present. We varied the strength of the unmeasured confounding (i.e. the unmeasured variable's effect on the probability of treatment and both outcome events) in different scenarios.
In both the Cox and Fine & Gray models, correlation between the unmeasured confounder and the probability of treatment created biases in the same direction (upward/downward) as the effect of the unmeasured confounder on the event-of-interest. The association between correlation and bias is reversed if the unmeasured confounder affects the competing event. These effects are reversed for the bias on the treatment effect of the competing event and are amplified when there are uneven treatment arms.
The effect of unmeasured confounding on an event-of-interest or a competing event should not be overlooked in observational studies as strong correlations can lead to bias in treatment effect estimates and therefore cause inaccurate results to lead to false conclusions. This is true for cause specific perspective, but moreso for a subdistribution perspective. This can have ramifications if real-world treatment decisions rely on conclusions from these biased results. Graphical visualisation to aid in understanding the systems involved and potential confounders/events leading to sensitivity analyses that assumes unmeasured confounders exists should be performed to assess the robustness of results.
竞争风险分析通常通过使用 Cox 或 Fine & Gray 模型的病因特异性或亚分布框架来实现。在观察性数据中,治疗效果的估计容易受到未测量混杂的影响,从而导致偏差。在竞争风险框架中,对这种偏差的研究有限。
我们设计了模拟研究,以检查存在未测量混杂时 Cox 和 Fine & Gray 模型中治疗效果估计的偏差。我们在不同的情况下改变了未测量混杂的强度(即未测量变量对治疗和两个结局事件的概率的影响)。
在 Cox 和 Fine & Gray 模型中,未测量混杂与治疗概率之间的相关性会导致与未测量混杂对感兴趣事件的影响方向相同(向上/向下)的偏差。如果未测量混杂会影响竞争事件,则关联与偏差之间的关系会反转。如果治疗组之间不均衡,这种效果会反转,并且对竞争事件的治疗效果的偏差会放大。
在观察性研究中,不应忽视未测量混杂对感兴趣事件或竞争事件的影响,因为强相关性可能导致治疗效果估计的偏差,并导致不准确的结果导致错误的结论。这对于病因特异性视角是正确的,但对于亚分布视角更是如此。如果基于这些有偏差的结果来做出实际的治疗决策,那么这可能会产生影响。应该进行图形可视化以帮助理解所涉及的系统和潜在混杂因素/事件,进行敏感性分析假设存在未测量混杂,以评估结果的稳健性。